CRAZYMEDS.US : www.crazymeds.us - 185 in TOP 100 MEDICAL SITES. Rating: 23000.

Description: An introduction to the Crazy Meds site, stating my philosophy that neurological meds suck donkey dong, but are far better than the alternative of unmedicated brain cooties.

Most popular searches: depression, www.crazyeds.us, vaccines, physician, neurological medications, www.craymeds.us, wwwcrazymeds.us, medical research, www.crzymeds.us, family practice, Pharmaceutical, ww.crazymeds.us, schizophrenia, www.crazymed.us, drug, www.crazymedsus, www.crazmyeds.us, epilepsy, www.carzymeds.us, psychiatric medications, www.crazyemds.us, manic-depression, crazy meds, wwwcrazymeds.us, drug rehab, Krankenhaus, ww.wcrazymeds.us, www.cazymeds.us, Cardiac, www.razymeds.us, patient, crazy, insane, Nachrichten, cholesterol, www.rcazymeds.us, wwwc.razymeds.us, bipolar, www.crazmeds.us, ww.crazymeds.us, doctor, www.crazymedsu.s, obesity, genome, www.crazymdes.us, mentally interesting, www.crazymds.us, www.crazymeds.us, blood pressure, www.crazymed.sus, medicine, autism, anxiety, www.crzaymeds.us, Immunology, www.crazymeds.u, www.crazymeds.s, asthma, health care, medical information, health, Allergy, www.crazymeds.su, www.crayzmeds.us, www.crazymesd.us, www.crazymes.us, www.crazymeds.us, mental illness

Bio-Reference Laboratories, Inc. Announces Continued Strong Growth Across All Laboratory Divisions (Business Wire)
ELMWOOD PARK, N.J.----Bio-Reference Laboratories, Inc. announced that the Company recorded current quarter revenues of $97,424, the best ever quarter in terms of revenues in corporate history and an increase of more than 25% over the $77,776 recorded in the third quarter, fiscal year 2008.
us.rd.yahoo.com

Democrats Defend Bill's Medicare Cuts
Democrats rejected GOP efforts to trim Medicare cuts in the health bill, saying the cuts would eliminate waste and won't erode benefits.
online.wsj.com

Gilead Sciences, Inc. Q3 2009 Earnings Call Transcript
Gilead Sciences, Inc. (GILD)Q3 2009 Earnings Call TranscriptOctober 20, 2009 4:30 pm ETComplete Story »
seekingalpha.com

Echo Therapeutics: Positive Developments for a Needle-Free Diabetes Monitoring System
Mike Havrilla submits:Echo Therapeutics (ECTE.OB) is a diabetes management company developing the needle-free Symphony Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wireless, transdermal solution for monitoring blood sugar levels and the needle-free Prelude SkinPrep System for transdermal drug delivery applications. On 11/19/09, the Company announced positive results in a pilot clinical study which included Prelude skin preparation and the placement of 10 Symphony tCGM biosensors on subjects with Type 1 or Type 2 Diabetes. Venous reference blood samples were taken from intravenous lines at 15-minute intervals for 24 hours and measured on a YSI 2300STAT PLUS laboratory analyzer to establish the gold standard / reference in this study, resulting in 97% accuracy for the Symphony tCGM System that was derived from approximately 900 glucose measurements with no adverse events related to the Prelude skin prep / permeation process.Complete Story »
seekingalpha.com

LabCorp is Scheduled to Present at the 28th Annual J.P. Morgan Healthcare Conference (Business Wire)
BURLINGTON, N.C.----Laboratory Corporation of AmericaÂ® Holdings today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 28th Annual J.P.
us.rd.yahoo.com